Related Experiment Video

Updated: May 20, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Neratinib (HKI-272) in the treatment of breast cancer

Sara López-Tarruella1, Yolanda Jerez, Iván Márquez-Rodas

  • 1Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Calle Dr Esquerdo 46, 28007, Madrid, Spain.

Future Oncology (London, England)
|July 7, 2012
PubMed

Insights

Neratinib, a pan-HER kinase inhibitor, shows promise for HER-2-positive breast cancer. This review covers its development and potential combination therapies for various treatment settings.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • HER-2-positive breast cancer is a significant subtype with evolving targeted therapies.
  • Neratinib is an orally available, irreversible, pan-HER kinase inhibitor.
  • Covalent drugs represent a targeted therapy approach with improving patient outcomes.

Purpose of the Study:

  • To review the molecular and clinical development of neratinib.
  • To focus on neratinib's role in breast cancer treatment.
  • To appraise potential combinations of neratinib with chemotherapy.

Main Methods:

  • Review of preclinical data.
  • Analysis of Phase III clinical trial outcomes.
  • Discussion of neratinib's development from early stages to clinical application.

Main Results:

  • Neratinib demonstrates potential as a targeted therapy for HER-2-positive breast cancer.
  • Combination strategies involving neratinib are being explored for metastatic, adjuvant, and neoadjuvant settings.
  • Clinical development has progressed from preclinical models to Phase III trials.

Conclusions:

  • Neratinib is a promising covalent drug for HER-2-positive breast cancer.
  • Further investigation into neratinib combinations may enhance treatment efficacy.
  • Neratinib's development exemplifies biologically tailored therapy in oncology.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...